– SER-109 met Phase 3 primary endpoint, showing a highly statistically significant 30.2% absolute reduction in the rate of C. difficile infection recurrence compared to placebo – – SER-109 was well ...

In its SEC filing, Seres Therapeutics Inc (NASDAQ: MCRB) disclosed it would not move forward with the planned SER-301 Phase 1b second study cohort. In its Q4 earnings release, Seres said that SER-301 ...

- Phase 1b study results demonstrate an impact on clinical remission and endoscopic improvement with a favorable safety profile in patients with mild-to-moderate ulcerative colitis- - Detailed ...

* Seres - misdiagnosis of C. Difficile recurrent infection in some patients, suboptimal dosing contributed to reported SER-109 Phase 2 study outcome * Seres - saw statistically significant increase in ...